

# Resource Summary Report

Generated by PRECISE-TBI on Jul 31, 2026

## Ablynx

RRID:SCR\_002940

Type: Tool

---

### Proper Citation

Ablynx (RRID:SCR\_002940)

---

### Resource Information

**URL:** <http://www.Ablynx.com>

**Proper Citation:** Ablynx (RRID:SCR\_002940)

**Description:** A biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases including inflammation, hematology, oncology and pulmonary disease.

**Abbreviations:** Ablynx

**Resource Type:** reagent manufacture, service resource, material service resource, production service resource

**Keywords:** nanobody, protein, antibody fragment, human disease, oncology, hematology, tumor, blood, therapy, therapeutic, pharmaceutical, drug product, drug

**Related Condition:** Inflammation, Cancer, Pulmonary disease, Thrombosis, Alzheimer's disease, Rheumatoid arthritis, Osteoporosis, Thrombotic thrombocytopenic purpura, Respiratory syncytial virus

**Resource Name:** Ablynx

**Resource ID:** SCR\_002940

**Alternate IDs:** nif-0000-30052

**Record Creation Time:** 20220129T080216+0000

**Record Last Update:** 20260731T042644+0000

---

### Ratings and Alerts

No rating or validation information has been found for Ablynx.

No alerts have been found for Ablynx.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 17 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [PRECISE-TBI](#) .

Coddens A, et al. (2020) An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics. Journal of immunological methods, 487, 112896.

Bauché D, et al. (2020) Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions. Journal for immunotherapy of cancer, 8(2).

Weiss RA, et al. (2019) Nanobodies that Neutralize HIV. Vaccines, 7(3).

Kazemi-Lomedasht F, et al. (2018) Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function. Iranian journal of basic medical sciences, 21(3), 260.

Veugelen S, et al. (2017) Screening and Characterization Strategies for Nanobodies Targeting Membrane Proteins. Methods in enzymology, 584, 59.

Arbabi-Ghahroudi M, et al. (2017) Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook. Frontiers in immunology, 8, 1589.

Van Audenhove I, et al. (2016) Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer. EBioMedicine, 8, 40.

Zhu M, et al. (2014) Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1. Journal of translational medicine, 12, 352.

Elvin JG, et al. (2013) Therapeutic antibodies: market considerations, disease targets and bioprocessing. International journal of pharmaceuticals, 440(1), 83.

Boruah BM, et al. (2013) Single domain antibody multimers confer protection against rabies infection. PloS one, 8(8), e71383.

Elsadek B, et al. (2012) Impact of albumin on drug delivery--new applications on the horizon. Journal of controlled release : official journal of the Controlled Release Society, 157(1), 4.

Kratz F, et al. (2012) Clinical impact of serum proteins on drug delivery. Journal of controlled release : official journal of the Controlled Release Society, 161(2), 429.

Wesolowski J, et al. (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Medical microbiology and immunology, 198(3), 157.

Dimitrov DS, et al. (2009) Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods in molecular biology (Clifton, N.J.), 525, 1.

Saerens D, et al. (2008) Single-domain antibodies as building blocks for novel therapeutics. Current opinion in pharmacology, 8(5), 600.

Hmila I, et al. (2008) VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin Aahl'. Molecular immunology, 45(14), 3847.

Harmsen MM, et al. (2007) Properties, production, and applications of camelid single-domain antibody fragments. Applied microbiology and biotechnology, 77(1), 13.